Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic

Dennis A. Conrad, John Christenson, Joseph L. Waner, Melvin I. Marks

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Thirty-three infants with predisposing conditions and/or severely symptomatic with respiratory syncytial virus (RSV) infection were treated with aerosolized ribavirin during a 12-week period at Oklahoma Children’s Memorial Hospital. These patients were compared with 97 untreated patients with RSV infection hospitalized during the same epidemic. Despite preconditions which selected for a more seriously ill treatment group, patients who received ribavirin showed prompter resolution of the illness than did untreated controls. Greatest clinical improvement in treated patients occurred between the first and second days of ribavirin therapy; mean ribavirin treatment duration was 4.5 days. Ten of 22 ribavirin-treated patients continued to excrete RSV after conclusion of antiviral therapy. No adverse hematologic, renal or metabolic effects occurred with ribavirin therapy. Our experience with ribavirin therapy during a major epidemic confirms and extends the results of previous controlled evaluations demonstrating this treatment safe and effective in high risk and seriously ill infants with RSV bronchiolitis and bronchopneumonia.

Original languageEnglish (US)
Pages (from-to)152-158
Number of pages7
JournalPediatric Infectious Disease Journal
Volume6
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Respiratory Syncytial Virus Infections
Ribavirin
Respiratory Syncytial Viruses
Therapeutics
Bronchopneumonia
Bronchiolitis
Antiviral Agents
Kidney

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Pediatrics, Perinatology, and Child Health

Cite this

Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. / Conrad, Dennis A.; Christenson, John; Waner, Joseph L.; Marks, Melvin I.

In: Pediatric Infectious Disease Journal, Vol. 6, No. 2, 1987, p. 152-158.

Research output: Contribution to journalArticle

@article{84fc099b847241b192a1e20e9392d19d,
title = "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic",
abstract = "Thirty-three infants with predisposing conditions and/or severely symptomatic with respiratory syncytial virus (RSV) infection were treated with aerosolized ribavirin during a 12-week period at Oklahoma Children’s Memorial Hospital. These patients were compared with 97 untreated patients with RSV infection hospitalized during the same epidemic. Despite preconditions which selected for a more seriously ill treatment group, patients who received ribavirin showed prompter resolution of the illness than did untreated controls. Greatest clinical improvement in treated patients occurred between the first and second days of ribavirin therapy; mean ribavirin treatment duration was 4.5 days. Ten of 22 ribavirin-treated patients continued to excrete RSV after conclusion of antiviral therapy. No adverse hematologic, renal or metabolic effects occurred with ribavirin therapy. Our experience with ribavirin therapy during a major epidemic confirms and extends the results of previous controlled evaluations demonstrating this treatment safe and effective in high risk and seriously ill infants with RSV bronchiolitis and bronchopneumonia.",
author = "Conrad, {Dennis A.} and John Christenson and Waner, {Joseph L.} and Marks, {Melvin I.}",
year = "1987",
language = "English (US)",
volume = "6",
pages = "152--158",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic

AU - Conrad, Dennis A.

AU - Christenson, John

AU - Waner, Joseph L.

AU - Marks, Melvin I.

PY - 1987

Y1 - 1987

N2 - Thirty-three infants with predisposing conditions and/or severely symptomatic with respiratory syncytial virus (RSV) infection were treated with aerosolized ribavirin during a 12-week period at Oklahoma Children’s Memorial Hospital. These patients were compared with 97 untreated patients with RSV infection hospitalized during the same epidemic. Despite preconditions which selected for a more seriously ill treatment group, patients who received ribavirin showed prompter resolution of the illness than did untreated controls. Greatest clinical improvement in treated patients occurred between the first and second days of ribavirin therapy; mean ribavirin treatment duration was 4.5 days. Ten of 22 ribavirin-treated patients continued to excrete RSV after conclusion of antiviral therapy. No adverse hematologic, renal or metabolic effects occurred with ribavirin therapy. Our experience with ribavirin therapy during a major epidemic confirms and extends the results of previous controlled evaluations demonstrating this treatment safe and effective in high risk and seriously ill infants with RSV bronchiolitis and bronchopneumonia.

AB - Thirty-three infants with predisposing conditions and/or severely symptomatic with respiratory syncytial virus (RSV) infection were treated with aerosolized ribavirin during a 12-week period at Oklahoma Children’s Memorial Hospital. These patients were compared with 97 untreated patients with RSV infection hospitalized during the same epidemic. Despite preconditions which selected for a more seriously ill treatment group, patients who received ribavirin showed prompter resolution of the illness than did untreated controls. Greatest clinical improvement in treated patients occurred between the first and second days of ribavirin therapy; mean ribavirin treatment duration was 4.5 days. Ten of 22 ribavirin-treated patients continued to excrete RSV after conclusion of antiviral therapy. No adverse hematologic, renal or metabolic effects occurred with ribavirin therapy. Our experience with ribavirin therapy during a major epidemic confirms and extends the results of previous controlled evaluations demonstrating this treatment safe and effective in high risk and seriously ill infants with RSV bronchiolitis and bronchopneumonia.

UR - http://www.scopus.com/inward/record.url?scp=0023225158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023225158&partnerID=8YFLogxK

M3 - Article

C2 - 3562136

AN - SCOPUS:0023225158

VL - 6

SP - 152

EP - 158

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 2

ER -